Tobias Feuchtinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tobias Feuchtinger has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Peter Lang
Department of Hematology/Oncology, Children's University Hospital, Tübingen, Germany
3 shared publications- Heiko-Manuel Teltschik
Department I - General Paediatrics, Hematology/Oncology, Children's Hospital, University Hospital Tuebingen, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany.
2 shared publications Michael Schumm
Department of Hematology/Oncology, Children's University Hospital, Tübingen, Germany
2 shared publications- Patrick Schlegel
University Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
2 shared publications - Rupert Handgretinger
Children’s University Hospital, University of Tuebingen
2 shared publications - Arndt Borkhardt
Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany
1 shared publication
Latest Publications
- 1 September 2015
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 38 (7) , 267-275
Identification of a Novel Immunodominant HLA-B*07
Adenovirus infections of immunocompromised patients, particularly following allogeneic hematopoietic stem cell transplantation, are associated with morbidity and mortality. Immunotherapy by adoptive transfer of hexon-specific and penton-specific T cells has been successfully applied, but many approaches are impeded by the low number of HLA class I-restricted adenoviral peptide epitopes described to date. We use a novel method to identify naturally presented adenoviral peptide epitopes from infected human cells, ectopically expressing defined HLA, using peptide elution and liquid chromatography-mass spectrometry analysis. We show that the previously described HLA-A*01:01-restricted peptide epitope LTDLGQNLLY from hexon protein is naturally presented, and demonstrate the functionality of LTDLGQNLLY-specific T cells. We further identify a novel immunodominant HLA-B*07:02-restricted peptide epitope VPATGRTLVL from protein 13.6 K, and demonstrate the high proliferative, cytotoxic, and IFN-γ-producing capacity of peptide-specific T cells. Lastly, LTDLGQNLLY-specific T cells can be detected ex vivo following adoptive transfer therapy, and LTDLGQNLLY-specific and VPATGRTLVL-specific T cells have memory phenotypes ex vivo. Given their proliferative and cytotoxic capacity, such epitope-specific T cells are promising candidates for adoptive T-cell transfer therapy of adenovirus infection.
- 1 September 2015
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 38 (7) , 267-275
Identification of a Novel Immunodominant HLA-B*07
Adenovirus infections of immunocompromised patients, particularly following allogeneic hematopoietic stem cell transplantation, are associated with morbidity and mortality. Immunotherapy by adoptive transfer of hexon-specific and penton-specific T cells has been successfully applied, but many approaches are impeded by the low number of HLA class I-restricted adenoviral peptide epitopes described to date. We use a novel method to identify naturally presented adenoviral peptide epitopes from infected human cells, ectopically expressing defined HLA, using peptide elution and liquid chromatography-mass spectrometry analysis. We show that the previously described HLA-A*01:01-restricted peptide epitope LTDLGQNLLY from hexon protein is naturally presented, and demonstrate the functionality of LTDLGQNLLY-specific T cells. We further identify a novel immunodominant HLA-B*07:02-restricted peptide epitope VPATGRTLVL from protein 13.6 K, and demonstrate the high proliferative, cytotoxic, and IFN-γ-producing capacity of peptide-specific T cells. Lastly, LTDLGQNLLY-specific T cells can be detected ex vivo following adoptive transfer therapy, and LTDLGQNLLY-specific and VPATGRTLVL-specific T cells have memory phenotypes ex vivo. Given their proliferative and cytotoxic capacity, such epitope-specific T cells are promising candidates for adoptive T-cell transfer therapy of adenovirus infection.
- Open Access
- 6 July 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (6) , 802-807
Anti‐leukaemic activity of a novel haploidentical‐transplantation approach employing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia
The treatment outcome of children with refractory acute leukaemia or relapse post‐stem cell transplantation is dismal. We report 10 children (non‐remission n = 7) who underwent a new haploidentical transplant approach utilizing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells. Nine patients had successful engraftment and no evidence of leukaemia. Acute and chronic graft‐versus‐host‐disease was observed in five and three patients, respectively; two patients died of treatment‐related toxicity. Seven patients relapsed after 7 (range 3–34) months, however two patients are alive at 6·5 and 7·0 years. This approach provides anti‐leukaemic activity even in heavily pre‐treated children but long‐term disease control requires further intervention.
- 6 July 2013
- Published by Wiley in British Journal of Haematology
- Vol. 162 (6) , 802-807
Open AccessAnti‐leukaemic activity of a novel haploidentical‐transplantation approach employing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia
The treatment outcome of children with refractory acute leukaemia or relapse post‐stem cell transplantation is dismal. We report 10 children (non‐remission n = 7) who underwent a new haploidentical transplant approach utilizing unmanipulated bone marrow followed by CD6‐depleted peripheral blood stem cells. Nine patients had successful engraftment and no evidence of leukaemia. Acute and chronic graft‐versus‐host‐disease was observed in five and three patients, respectively; two patients died of treatment‐related toxicity. Seven patients relapsed after 7 (range 3–34) months, however two patients are alive at 6·5 and 7·0 years. This approach provides anti‐leukaemic activity even in heavily pre‐treated children but long‐term disease control requires further intervention.
- 17 August 2012
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1266 (1) , 161-170
Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation
Haploidentical hematopoietic stem cell transplantation is a curative alternative option for patients without an otherwise suitable stem cell donor. In order to prevent graft‐versus‐host disease (GvHD), different in vitro and in vivo T cell–depletion strategies have been developed. A delayed immune reconstitution is common to all these strategies, and an impaired immune function after haploidentical transplantation with subsequent infections is a major cause of deaths in these patients. In addition to in vitro and in vivo T cell–depletion methods, posttransplant strategies to rapidly rebuild the immune system have been introduced in order to improve the outcome. Advances in in vitro and in vivo T cell–depletion methods, and adoptive transfer of immune cells of the innate and specific immune system, will contribute to reduce the risk of GvHD, lethal infections, and the risk of relapse of the underlying malignant disease.
- 17 August 2012
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1266 (1) , 161-170
Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation
Haploidentical hematopoietic stem cell transplantation is a curative alternative option for patients without an otherwise suitable stem cell donor. In order to prevent graft‐versus‐host disease (GvHD), different in vitro and in vivo T cell–depletion strategies have been developed. A delayed immune reconstitution is common to all these strategies, and an impaired immune function after haploidentical transplantation with subsequent infections is a major cause of deaths in these patients. In addition to in vitro and in vivo T cell–depletion methods, posttransplant strategies to rapidly rebuild the immune system have been introduced in order to improve the outcome. Advances in in vitro and in vivo T cell–depletion methods, and adoptive transfer of immune cells of the innate and specific immune system, will contribute to reduce the risk of GvHD, lethal infections, and the risk of relapse of the underlying malignant disease.
- 30 September 2011
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 24 (3) , 443-452
Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children
- 30 September 2011
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 24 (3) , 443-452
Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children
- 23 February 2011
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 28 (4) , 334-337
Long-Term Remission After First-Line Single-Agent Treatment with Arsenic Trioxide of Relapsed Acute Promyelocytic Leukemia in an 8-Year-Old Boy
Arsenic trioxide (ATO) has been proven to be highly effective in adults with newly diagnosed or relapsed acute promyelocytic leukemia (APL). Only very limited data are published on the use of ATO as a single agent for first-line therapy of relapsed APL. The authors present a case of a 8-year-old boy with a bone marrow relapse of APL 7 years after first diagnosis, who achieved durable molecular remission with ATO as single agent: induction therapy for 12 weeks, consolidation for 4 weeks, then 6 cycles of 10 days over a period of 6 months. In total, 140 doses of ATO (0.15 mg/kg/day) were given (21 mg/kg). Consecutive promyelocytic leukemia-retinoic acid receptor α (PML-RARα) RT-PCR analyses were negative with a follow-up of 48 months. Acute or late side effects of arsenic were not observed. At present, the boy is in complete remission 4 years after the diagnosis of the relapse.
- 23 February 2011
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 28 (4) , 334-337
Long-Term Remission After First-Line Single-Agent Treatment with Arsenic Trioxide of Relapsed Acute Promyelocytic Leukemia in an 8-Year-Old Boy
Arsenic trioxide (ATO) has been proven to be highly effective in adults with newly diagnosed or relapsed acute promyelocytic leukemia (APL). Only very limited data are published on the use of ATO as a single agent for first-line therapy of relapsed APL. The authors present a case of a 8-year-old boy with a bone marrow relapse of APL 7 years after first diagnosis, who achieved durable molecular remission with ATO as single agent: induction therapy for 12 weeks, consolidation for 4 weeks, then 6 cycles of 10 days over a period of 6 months. In total, 140 doses of ATO (0.15 mg/kg/day) were given (21 mg/kg). Consecutive promyelocytic leukemia-retinoic acid receptor α (PML-RARα) RT-PCR analyses were negative with a follow-up of 48 months. Acute or late side effects of arsenic were not observed. At present, the boy is in complete remission 4 years after the diagnosis of the relapse.